Obeldesivir for COVID-19 Is Safe, Reduces Time to Symptom Relief in High-Risk Patients

My note: Would like to see study on this drug with endpoints like time to recovery, severity of symptoms, long-term follow-up for post-acute symptoms. Not holding my breath. This is, after all, Giliad, the maker of remdesivir. Still, potential early treatment option here:

465 adults received either obeldesivir or a placebo for 5 days. The results showed that those on obeldesivir had a 0% hospitalization rate and lower mortality compared to 0.5% in the placebo group.

Patients taking obeldesivir also experienced quicker symptom relief and greater reductions in the virus levels. Overall, the drug was found to be generally safe and well-tolerated.

#obeldesevir #early treatment #treatment #antiviral

·infectiousdiseaseadvisor.com·Oct 23, 2024

Obeldesivir for COVID-19 Is Safe, Reduces Time to Symptom Relief in High-Risk Patients

A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells

“the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells.”

the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells.

#UNI418 #antiviral #PIKfyve and PIP5K1C inhibitor #treatment #early treatment

·nature.com·Sep 2, 2024

A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells